prikaz prve stranice dokumenta CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients
  Download
PDF 271.56 KB
Scientific paper - Original scientific paper
CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients
International Journal of Molecular Sciences, 25 (2024), 13; 7412. https://doi.org/10.3390/ijms25137412
Nekić, Jasna; Stanković Matić, Ivana; Rački, Valentino; Janko Labinac, Dolores; Vuletić, Vladimira; Kapović, Miljenko; Ristić, Smiljana; Peterlin, Borut; Starčević Čizmarević, Nada

Cite this document

Nekić, J., Stanković Matić, I., Rački, V., Janko Labinac, D., Vuletić, V., Kapović, M. ... Starčević Čizmarević, N. (2024). CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients. International Journal of Molecular Sciences, 25. (13). doi: 10.3390/ijms25137412

Nekić, Jasna, et al. "CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients." International Journal of Molecular Sciences, vol. 25, no. 13, 2024. https://doi.org/10.3390/ijms25137412

Nekić, Jasna, Ivana Stanković Matić, Valentino Rački, Dolores Janko Labinac, Vladimira Vuletić, Miljenko Kapović, Smiljana Ristić, Borut Peterlin and Nada Starčević Čizmarević. "CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients." International Journal of Molecular Sciences 25, no. 13 (2024). https://doi.org/10.3390/ijms25137412

Nekić, J., et al. (2024) 'CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients', International Journal of Molecular Sciences, 25(13). doi: 10.3390/ijms25137412

Nekić J, Stanković Matić I, Rački V, Janko Labinac D, Vuletić V, Kapović M, and sur.. CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients. International Journal of Molecular Sciences [Internet]. 2024 July 05 [cited 2024 November 14];25(13). doi: 10.3390/ijms25137412

J. Nekić, et al., "CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients", International Journal of Molecular Sciences, vol. 25, no. 13, July 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:033424. [Accessed: 14 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients
AuthorJasna Nekić
AuthorIvana Stanković Matić
AuthorValentino Rački
AuthorDolores Janko Labinac
AuthorVladimira Vuletić
AuthorMiljenko Kapović
AuthorSmiljana Ristić
AuthorBorut Peterlin
AuthorNada Starčević Čizmarević
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Biology and Medical Genetics)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Neurology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Human Genetics, Genomics and Proteomics
Abstract (english)
The aim of the present study was to investigate the impact of CCR5 Δ32 and CTLA-4 polymorphisms on the response to IFN-β treatment in our cohort of MS patients from Croatia and Slovenia. Genomic DNA was obtained from 295 MS patients (230 female; 65 male) classified as responders (n = 173) and non-responders (n = 122) based on clinical criteria for treatment efficacy. Genotyping was performed via PCR/PCR-RFLP. No significant differences in the genotype/allele frequencies of CCR5Δ32 and CTLA-4 +49 A/G were detected between male responders and non-responders. A significantly higher prevalence (p = 0.039) of the CTLA-4 +49 AA genotype was found in female responders (42.1%) compared to non-responders (28.9%). Using multiple forward regression analysis, the CTLA-4 +49 AA genotype significantly predicted a positive response to IFN-β therapy in females (p = 0.011) and contributed to 4.5% of response variability. Furthermore, the combined presence of the CCR5Δ32 wtwt/CTLA-4 +49 AA genotype significantly predicted a positive response to treatment in females (p = 0.025). The age at disease onset, pretreatment relapse rate, and baseline EDSS score were not reliable predictors of treatment response in MS patients. Our results indicate that the presence of the CCR5Δ32 polymorphism was not associated with the response to IFN-β treatment, whereas the CTLA-4 +49 polymorphism showed a positive correlation with an optimal response in female patients.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleInternational Journal of Molecular Sciences
Numberingvol. 25, no. 13, 7412
e-ISSN1422-0067
DOIhttps://doi.org/10.3390/ijms25137412
URN:NBNurn:nbn:hr:184:033424
Publication2024-07-05
ProjectNumber: uniri-biomed-18-137
Title (croatian): Farmakogenetika multiple skleroze: odgovor na imunomodulacijsku terapiju
Title (english): Farmacogenetics of multiple sclerosis: response to disease-modifying therapy
Leader: Nada Starčević Čizmarević
Jurisdiction: Croatia
Document URLhttps://www.mdpi.com/1422-0067/25/13/7412
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-11-11 09:51:54